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Summary To determine if chemotherapy dose intensity influences treatment outcome in advanced ovarian
cancer, all randomised studies of first line chemotherapy, published between 1975 and 1989, were analysed for
relationships between planned dose intensity and (a) objective response and (b) median survival. Total dose
intensity of each study regimen was calculated and a weighted regression model providing for systemic
differences in response or survival among studies was utilised. Hence, treatment arms of different studies were
never directly compared. In addition, relative dose intensities of individual drugs within combinations was
similarly evaluated. The improvement in objective response rate when adding one unit of total dose intensity
ranged between 12% and 16% depending on baseline response rate. The improvement in median survival
when adding one unit of total dose intensity ranged between 2 and 4 months. One unit of total dose intensity
corresponds to, for example, 20 mg m2 week of cisplatin, or 25 mg m2 week of doxorubicin, or 350 mg m2 week
of cyclophosphamide. The analysis of individual drugs suggested that doxorubicin and the platinum com-
pounds were about equally effective, with cyclophosphamide being less effective. The methodological benefits
and limitations of the approach used and the implication of the results are discussed.
Cancer of the ovary is the fifth most common neoplasm
among women (American Cancer Society, 1986). Approx-
imately 70% of patients present with advanced stage disease
at diagnosis and 85% of them eventually die as a result of
their disease (Richardson et al., 1985). Long term survival is
disappointingly low. Partially for this reason, a plethora of
drugs, combinations and schedules are used in attempts to
derive the most benefit from chemotherapy with acceptable
toxicity. It is surprising, therefore, that, despite the abundant
experimental and retrospective clinical evidence supporting
the importance of drug dosage and time relationships
(Bonadonna & Valgussa, 1981; De Vita, 1986), no ran-
domised trials specifically designed to answer the dose inten-
sity question in ovarian cancer have yet been conducted.
Dose intensity, defined as the amount of drug delivered per
unit of time and usually standardised to body area surface as
mgm2wk (Green et al., 1980), correlates with outcome of
chemotherapy in many cancers and in ovarian cancer there is
some retrospective evidence that it could be important (Levin
& Hryniuk, 1987a,b). These retrospective analyses have, how-
ever, been subject to criticism on methodologic grounds
(Henderson et al., 1988). We felt that the methodology of
meta-analyses of randomised clinical trials could be useful in
attempting to get more reliable information from retrospec-
tive studies (L'Abbe et al., 1987). Therefore, given the
importance of the dose intensity issue and the possibility of
utilising retrospective data in a more methodologically sound
way, we undertook an analysis of the results of randomised
clinical trials in ovarian cancer to determine if a relationship
between dose intensity and outcome exists in advanced
ovarian cancer. We attempted to determine which commonly
used agents alone or in combination show the best dose
intensity outcome relationships.
Materials and methods
Studypopulation
We utilised only randomised clincial trials of first line
chemotherapy for advanced ovarian cancer patients pub-
lished in the English language and in complete form between
1975 and 1989 inclusive. Studies were identified by searching
through MEDLINE for specific medical key words (e.g.:
ovarian neoplasm, human, random allocation, first line
chemotherapy). Trials were not included in this analysis if (a)
they were preliminary reports; (b) they were phase I or phase
II; (c) if more than 15% of the patients were previously
treated with chemotherapy; or (d) if more than 15% of the
patients were stage I or II. Studies with no information about
either survival or objective response information were drop-
ped from the analysis. Thirty-two out of 47 initially identified
studies were available for analysis of the association between
dose intensity and objective response. Twenty-six out of 47
were available for the correlation of dose intensity and sur-
vival. Twenty-five of these studies had both objective res-
ponse and survival information. Table I show the principal
characteristics of the studies included in the analyses. A
complete list of referenced studies is given in the Appendix.
Statistical analysis
For each drug, raw intensity was defined as the planned rate
of delivery expressed on a mg m2 wk basis. The relative dose
intensity of a particular drug was then expressed using the
'equalised standard method' (Levin & Hryniuk, 1987a) as the
raw intensity divided by the dose intensity of that same drug
which produces a 40% objective response rate in previously
untreated patients. Table II shows the reference equi-
response dose intensities for each drug analysed. The total
dose intensity for a particular regimen is the sum of the
relative dose intensities for each constituent drug of the
regimen. The analyses utilised two different models. The first
is
Yij = a, + P Iij + eij
where yij is the observed log odds of objective response or log
median survival and Iij is the total dose intensity of the j'th
treatment arm of the i'th study. The term oi represents the
fixed effect of the i'th study and eij accounts for random
error. The unknown regression coefficient P estimates the
magnitude of the relationship between dose intensity and
outcome. The inclusion of a separate fixed effect for each
study provides for systematic differences in response or sur-
vival among the studies due to patient selection, response
assessment, etc. Therefore, in estimating dose intensity effects
(p), treatment arms of different trials are never compared; the
estimates are based only on comparisons of arms of the same
clinical trial.
In the second model, we desired to examine the effects of
the relative dose intensities of each drug on outcome holding
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Table I Data from 33 studies considered for the analysis
Appendix
reference Study Regimens'
I Barlow mel
act/5fu/ctx
2 Young mel
ctx/hex/5fu/met
3 Edmonson ctx
adm/ctx
4 Barlow ctx/5fu
ctx/met
5 MRC ctx/hex/met
ctx
6 Bruckner met/thi
ddp/adm
.ddp
7 CarmoPereira ctx/hex/5fu/met
ctx
8 Schwartz ctx/hex
adm/ctx
9 Bell chl
ddp/ctx
10 Omura adm/ctx
hex/mel
mel
11 CarmoPereira ddp/adm/hex
ctx
12 Edwards adm/ctx/hex
ddp/mel
13 Neijt ctx/hex/Sfu/met
ddp/adm/ctx/hex
14 Lambert ctx
ddp
15 Bruckner mel
met/thi
adm/ctx/5fu
adm/ctx/Sfu/met
16 Sessa adm/ctx/hex
ddp/adm/ctx
17 Edmonson ddp/adm/ctx
ddp/ctx
18 Aabo ctx
adm/ctx/Sfu
19 Williams chl
ddp/adm/ctx
20 Omura adm/ctx
ddp/adm/ctx
21 GGCOS chl
ddp/chl
22 Conte ddp/ctx
ddp/adm/ctx
23 Bertelsen ddp/ctx
ddp/adm/ctx
24 Adams mel
adm/ctx/5fu
25 Neijt ddp/ctx
ddp/adm/ctx/hex
26 GICOG ddp
ddp/ctx
ddp/adm/ctx
27 Trope mel
adm/mel
28 Hernadi ddp/ctx
ddp/edm/ctx
ddp/adm/ctx
29 Tomirotti ddp
ddp/adm/ctx
30 Leonard pre
ddp/pre/hex
31 Omura ddp/ctx
ddp/adm/ctx
32 Mangioni cbdca
ddp
33 Adams cbdca
ddp
Relative No. Median
dose assessable % obj. No. of survival
intensity obj. resp. response deaths (months)
1.14 49 34.7 47 12
1.67 49 53.1 46 12
1.14 37 54.1 26 17
0.43 40 75.0 18 20
0.95 35 31.4 34 12
1.01 36 36.1 34 12
1.29 22 31.8 20 19
1.71 21 66.7 17 19
1.81 115 21.7 93 11
1.43 120 31.7 82 12
0.45 14 35.7 14 11
1.13 15 80.0 16 19
0.63 13 30.8 15 20
2.41 28 35.7 27 10
0.57 29 62.1 27 11
1.03 20 50.0 - 14
1.11 17 58.8 - 17
0.67 13 23.1 10 17
1.54 13 69.2 10 18
1.15 72 48.6 92 12
1.30 97 51.6 120 13
1.00 64 37.5 75 14
1.09 26 38.5 - 11
1.52 27 66.7 - 12
1.42 71 31.0 59 26
1.89 82 37.8 72 30
1.91 88 50.0 71 20
2.32 84 78.6 54 31
1.43 37 67.6 30 12
1.50 49 75.5 30 19
1.00 40 35.0 71 12
0.23 36 44.4 66 12
1.50 52 55.8 74 14
0.87 39 48.7 72 15
1.51 56 66.1 43 23
1.84 60 70.0 40 24
1.48 45 57.8 - 24
1.46 52 59.6 - 27
0.75 48 27.1 58 12
1.50 58 46.6 70 14
0.75 43 23.3 38 11
2.11 40 65.0 34 13
1.15 120 47.5 168 16
1.98 107 75.7 154 19
0.75 182 12.6 - 15
1.38 180 16.1 - 16
1.06 35 54.3 37 22
1.51 32 56.3 29 26
1.11 71 67.6 33 21
1.51 71 74.7 34 26
0.57 17 11.8 - 6
1.93 16 43.8 - 8
1.96 94 74.5 63 24
2.32 88 79.6 57 31
0.63 173 51.5 119 19
1.09 174 61.5 119 21
1.59 169 71.0 103 24
1.14 75 26.7 65 10
0.86 73 54.8 70 19
1.95 16 62.5 14 13
2.24 16 87.5 12 14
2.37 16 87.5 11 27
0.75 17 47.1 15 18
2.21 19 47.4 13 19
1.00 36 36.1 - 12
1.79 40 40.0 - 15
1.78 - - 102 31
1.98 - - 88 39
1.25 82 61.0 34 21
1.25 81 72.8 24 31
1.25 40 67.5 - 9
1.25 40 47.5 12
aact
=actinomycin; 5fu = fluorouracil; ctx =cyclophosphamide; mel =melphalan; hex =hexamethyl- melamine; adm = doxorubicin; met = methotrexate;ddp
=cisplatin; thi =thiotepa;chl=chlorabucil;edm = epi- rubicin; cbcda = carboplatin; pre =prednimustine.192 V. TORRI et al.
Table II Dose intensity units for a 40% response rate
Drug DI (mgm2 week) Reference
Cisplatin 20 Levin & Hryniuk, 1987a
Carboplatin 80 Mangioni et al., 1989
Doxorubicin 25 Levin & Hryniuk, 1987a
Cyclophosphamide 350 Levin & Hryniuk, 1987a
Chlorambucil 0.029 Levin & Hryniuk, 1987a
Melphalan 0.11 Levin & Hryniuk, 1987a
Thiotepa 40 Young et al., 1974
Prednimustine 217 Johnsson et al., 1979
Hexamethylmelamine 1750 Levin & Hryniuk, 1987a
5-FU 600 Young et al., 1974
Methotrexate 188 Young et al., 1974
the dose intensities of the other drugs fixed. However,
because of the limited number of treatment arms with some
of the drugs, we grouped similar acting agents together when
their was insufficient data (see Table III for the groupings).
The multiple linear regression model used is
y = a +p3PIf + pAlij +fCl!j +p1I3 + HIHj+ +PMIM+ eij
where for the j'th treatment arm of the i'th study, If, IA, IV,
I°, IH' and I,M are the dose intensities for the platinum com-
pounds, doxorubicin, cyclophosphamide, other alkylating
agents, hexamethylmelamine, and antimetabolites, respec-
tively. The partial regression coefficients (P's) represent the
effect of changing the dose intensity of one agent on the
outcome holding the doses of all the other agents fixed.
Both models used a weighted regression analysis. For the
analysis of the relationship between log odds of objective
response and dose intensity, the weights were
wij=nij Pij (I-Pij)
where nij is the sample size and Pij is the observed response
rate for arm j of the study i. For the analysis of the relation-
ship between log median survival and dose intensity, the
weights were
wij = the number of deaths in arm j of the study i.
These weights insure that study arms with more information
contribute more to the regressions.
For both models, partial regression plots (Velleman &
Welsch, 1981) were used to display the data. For the first
model, these plots are of the outcomes adjusted for study
effects, (yij-yi) vs the total dose intensity adjusted for study
effects, (Iij-Ii), where yi and Ii are weighted average outcome
and weighted average dose intensity respectively for the i'th
study. The slope of a weighted linear regression fit to this
data is the regression coefficient P relating dose intensity to
outcome. For the second model, plots can be obtained for
agent X as follows: First, the outcome is regressed on all the
other agents and the study effects (using the weights).
Secondly, the total dose intensity is regressed on all the other
agents and study effects (using the weights). Then the
residuals from the first regression are plotted against the
residuals from the second regression. The slope of a weighted
linear regression fit to this data is the partial regression
coefficient P1 relating dose intensity of agent X to outcome.
In all plots, bubbles with area proportional to the weights are
used as a plotting symbol so that one can see which treat-
ment arms are contributing more to the estimated regression
coefficients. Additionally, in all plots the axes have been
relabeled for ease of interpretation.
The null hypothesis that the inclusion of the study effects
(os's) was unnecessary in the modeling was tested with an F
test.
Results
Examination of the relationship between response and total
dose intensity was performed using the regression model
defined in the Methods section. The estimate of the regres-
sion coefficient P relating log odds of response total dose
intensity was 0.64 (SE = 0.18, P = 0.0008). To put this
regression coefficient on a more interpretable scale, Table IV
displays the predicted response rate for a 1.0 unit increase in
dose intensity given certain baseline response rates. For
example, an increase in cisplatin dose of 1Omg m2wk and
cyclophosphamide dose of 175 mg m2wk would correspond
to a 1.0 ( = 0.5 + 0.5) increase in dose intensity as defined in
Table II. If the baseline response rate was 40%, then this
increase would lead to a response rate of 56% (90%
confidence interval = 48%-63%). We see in Table IV that
for the baseline rates considered that an increase in 1 unit of
dose intensity yields predicted increases in response rates of
12% to 16%.
When analysing the median survival and total dose inten-
sity relationship, the estimate of P was 0.14 (SE = 0.06,
P = 0.040). Table V displays the predicted increase in median
Table IV Predicted response rate for I unit increase dose intensity as
defined in Table I
Baseline Predicted 90%
response rate response rate confidence interval
(%) (%) (%)
40 56 48-63
50 66 59-72
60 74 68-79
70 82 77-86
TableV Predicted median survival for I unitincreasedose intensity as
defined in Table I
Baseline median Predicted median 90%
survival survival confidence interval
(%) (%) (months)
15 17 15- 19
18 21 19-23
21 24 22-27
24 28 25-31
Table III Multiple regression analyses on dose intensity of classes of individual agents
Log Odds ofResponse Log Median Survival
Agents p SE P-value p SE P-value
Platinum 0.92 0.23 0.0003 0.23 0.08 0.0092
(cisplatin + carboplatin)
Doxorubicin 0.78 0.31 0.017 0.29 0.10 0.0083
Cyclophosphamide 0.50 0.27 0.068 - 0.11 0.11 0.31
Other alkylating agents - 0.06 0.27 0.83 - 0.02 0.10 0.81
(chlorambucil + melphalan
+ thiotepa + prednimustine)
Hexamethylmelamine - 0.18 0.66 0.78 0.17 0.25 0.50
Antimetabolites - 0.16 0.51 0.75 - 0.02 0.19 0.90
(5FU + methotrexate)DOSE INTENSITY ANALYSIS IN ADVANCED OVARIAN CANCER
survival for a 1.0 unit increase in dose intensity. The increase
is in the range of 2 to 4 months.
The partial regression plots for response rates and median
survival are given in Figures 1 and 2. The weaker relation-
ship between survival and dose intensity is reflected in the
larger amount of scatter in Figure 2, although both figures
have considerable scatter.
Table III presents the results of using the second model for
examining the effects of individual drugs. For response, there
is a positive relationship between dose intensity for platinum
(P= 0.0003), doxorubicin (P= 0.017), and cyclophospha-
mide (P = 0.068). Table VI displays the predicted response
rates for an increase in 1.0 unit of dose intensity for these
agents individually, or in combination (1/3 unit increase for
each drug). For an increase in 1.0 unit of dose intensity,
cyclophosphamide is relatively less effective than the
platinum compounds or doxorubicin. This can also be seen
in the partial residual plots (Figure 3) where there the smaller
dose/response association can be seen for cyclophosphamide.
Although no association was found for hexamethylmel-
amine or the antimetabolites, notice that the standard errors
for these agents were considerably larger than for the other
agents. This suggests that there was insufficient studies with
high enough doses of these agents to be able to estimate the
association well. The correct interpretation of these results is
not that there is no dose-response for these agents, but
instead that the data was insufficient to make a statement
concerning the dose response.
For the relationship between dose intensity and median
survival, there was a significant and positive association for
platinum (P = 0.0092) and doxorubicin (P = 0.0083). The
association for cyclophosphamide was paradoxically nega-
tive, although not statistically significant. The predicted
effects on median survival for a 1.0 unit increase in dose
intensity are given in Table VII. The partial residual plots are
given in Figure 4.
When the analyses were repeated restricted to those 25
studies that had both response and survival data available,
the results were very similar to those reported above with one
exception. The regression coefficient for the effect of cyclo-
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Figure 2 Partial regression plot for relative median survival vs
relative dose intensity. Plot represents the increase in median
survival for a change in dose intensity within any given study.
Vertical axis is on a log scale.
Table VI Predicted response rate for 1 unit increase in dose intensity
(DI)
Predicted response rate
(%)
Baseline I unit DI 1/3 unit DI
response rate increasefor increasefor all
(%) single agent three agents
pa Aa Ca PACa
40 63 59 52 58
50 72 69 62 68
60 79 77 71 76
70 85 84 79 83
oP= cisplatin and/or carboplatin; A = doxorubicin; C = cyclo-
phosphamide.
0
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00
phosphamide dose intensity on response rates dropped from
0.50 to 0.22. This suggests that the difference in the effects of
cyclophosphamide on response and survival displayed in
Table III may be partly explained by the particular studies
that were included in each analysis.
The study effect was large in all the analyses (P<0.0001).
Discussion
0.3x 0.3 .....................,.......................I.,.
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Relative dose intensity
Figure 1 Partial regression plot for relative odds of response vs
relative dose intensity. Plot represents the increase in odds of
response for a change in dose intensity within any given study.
Vertical axis is on a log scale.
The importance of cumulative dose of planned therapy has
been suggested (Richardson et al., 1985; Geller et al., 1990)
in breast cancer and the role of dose rate have been
emphasised in several neoplasms (Levin & Hryniuk, 1987a;
Meyer et al., 1991; Lasa et al., 1991). In ovarian cancer the
findings suggested a strong relationship between dose inten-
sity and survival. However these results have been criticised
because of the possibility of biases, especially the possibility
that better prognosis patients are selected for trials that
employ more intensive regimens and that publication bias
favours the reporting of small non-randomised trials of aggres
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Figure 3 Partial regression plots for relative odds of response vs adjusted relative cisplatin dose (left panel), doxorubicin dose
(middle panel), and cyclophosphamide dose (right panel). Plots represent the increase in odds of response for a change in dose
intensity within any given study holding the doses of the other agents fixed. Vertical axes are on log scales.
sive regimens that result in spuriously high response rates.
Our study tried to overcome some of these potential biases.
We restricted attention to randomised trials and avoided
comparing patients in one trial with those in another trial:
comparison is made only within each trial because the model
Table VII Predicted median survival for 1 unit increase in Dose
Intensity (DI)
Predictead median survival
(mon-ths)
Baseline I unit DI 1/3 unit DI
median survival increasefor increasefor all
(%) single agent three agents
pa Aa ca PAO
15 19 20 __b 17
18 23 24 21
21 27 28 24
24 30 32 28
ap = cisplatin and/or carboplatin; A =doxorubicin; C =cyclo-
phosphamide. bCyclophosphamide dose-response is negative for
median survival.
incorporates study specific effects. When the present data is
analysed without study effects in the model, a similar dose-
response relationship is observed for response rates. How-
ever, the association of dose intensity and median survival is
estimated to be much larger (p = 0.32, SE = 0.09). This imp-
lies that a 1.0 unit increase in dose intensity would yield a
median survival advantage of 6-9 months, rather than the
2-4 months estimated with the study effects in the model.
Given the large estimated study effects, we believe the model
with their inclusion is more reliable.
The methods ofthis paper do not solve the concerns about
assumptions of the dose intensity calculation, particularly in
regards to multidrug regimens (Gelman, 1990; Gelman &
Neuberg, 1991). Limitations of the design of the clinical trials
employed made it impossible to evaluate synergistic effects or
schedule dependencies. There are other issues that can also
influence the interpretation of our results. Firstly, we used
only published data and hence results could be affected by
publication bias (Begg & Berlin, 1989), which could be fur-
ther accentuated by the fact that only between half and
two-thirds of the published studies had enough data for
inclusion in this study. Secondly, median survival may not
be the most sensitive endpoint for measuring the impact of
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intensity within any given study holding the doses of the other agents fixed. Vertical axes are on log scales.
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dose intensity. Unfortunately, long term survival, perhaps a
more sensitive endpoint, was not available in many studies.
Moreover, it was not possible to evaluate the effect of the
subsequent management on survival. This could partially
account for the less impressive relationship between dose-
intensity and survival compared to dose-intensity and res-
ponse. Patients failing first-line non-platinum chemotherapy
are more likely to respond to second-line treatment with
platinum than are patients failing first-line platinum who
receive other second-line treatments including second-line
platinum. This observation has been used to partially explain
the lack of survival benefit in randomised trials comparing
platinum compounds with a single alkylating agent (Ad-
vanced Ovarian Cancer Trialist Group, 1991). Thirdly, we
can estimate the relationship between a specified increase in
total dose intensity and outcome (response and survival), but
we cannot really estimate the shape of the relationship. Our
estimates were based on the assumption of linearity, but the
data were not sufficient to distinguish different shapes while
controlling for study differences.
Nevertheless, the results presented here confirm that there
is a relationship between overall dose intensity and response
or survival after adjusting for study effects. For survival, this
relationship seems smaller than the one found by Levin and
Hryniuk (1987a). The units of dose intensity for individual
drugs are defined by Table I1 and an increase in relative dose
intensity of two units generally is accompanied by a major
increase in serious or life threatening toxicities. It also has to
be considered that there were few studies in which arms
differed by more than one unit of total dose-intensity, and,
consequently, it is not possible to make any comment on
whether the relationship between outcome and dose-intensity
continue beyond that range. This less optimistic result con-
cerning dose-intensity and survival is in better agreement
with the disappointing situations in advanced disease, but
also indicates that the development of effective toxicity
reduction agents would be of benefit in this chemosensitive
neoplasm. The fact that the regression coefficients for sur-
vival are about the same for cisplatin and doxorubicin
confirms the importance of using these drugs at an intensive
rate. In addition, these results confirm the role ofcisplatin in
advanced ovarian carcinoma, in agreement with the AOCTG
meta-analysis (Advanced Ovarian Cancer Trialist Group,
1991). They also underline the important role ofdoxorubicin,
helping in the interpretation of the finding of a recent meta-
analysis (Ovarian Cancer Meta-Analysis Project, 1991),
which showed a superiority of a CAP over a CP regimen.
In summary, the validity of the dose intensity hypothesis in
advanced ovarian cancer is substantiated based on the utilisa-
tion of improved methodology for analysis of available data.
This approach suggests hypotheses for the intensification of
therapy and reinforces the importance of formally evaluating
dose intense regimens in prospective randomised clinical
trials.
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